Symposia


Symposia at a Glance

Pre-registration required
CDA Annual Conference Symposia
Open links below for more details

A New Era in the Management of Atopic Dermatitis

Speakers

Kim Papp, MD, PhD, FRCPC, FAAD
Jonathan Silverberg, MD, PhD, MPH

Learning Objectives

Review the pathophysiology of Atopic Dermatitis.
Evaluate emerging clinical data for biologics in the management of Atopic Dermatitis.
Patient cases and perspectives in the management of Atopic Dermatitis.

Program Description

A podium presentation with audience interactivity & panel Q&A with Dermatology thought leaders including a key international Dermatology Opinion leadersDr. Jonathan Silverberg and Dr. Kim Papp.

Pathophysiology- a presentation on the pathophysiology of atopic dermatitis encompassing the role of key cytokines which describe the immune pathways. A discussion on points of intervention will also be included.  Audience participation via electronic Q&A will be incorporated. (10mins)

An overview of emerging clinical data for biologics that are currently in development and including the newly approved Dupilumab.  This presentation will build upon the previous discussion on points of intervention in the immunopathways that drive atopic dermatitis.  Audience participates by electronic Q&A. (25mins)

Perspectives in the management of atopic dermatitis will be presented through patient cases. The presenter will include the audience in discussion pertaining to the management of each case.  Discussion will include recommended approaches to patient management. Patient cases will include patients with atopic comorbidities. (25mins)

Narrowing the Target to Treat Psoriasis: IL23 p19

Speakers

Melinda Gooderham, MSc, MD, FRCPC
Mark Kirchhoff, MD, PhD, FRCPC
Perry Grewal, MD, FRCPC
Vincent Richer, MD, FRCPC

Learning Objectives

Understand new developments in our understanding of existing modes of action to treat psoriasis.
Review the clinical data supporting the new indication of Guselkumab (IL-23 p19) for the treatment of moderate to severe psoriasis.
Examine the evolution of the safety of biologics in treating psoriasis.
Discuss new therapeutic options and patient co-morbidity considerations.

Program Description

Join us for an interactive panel presentation with a mixture of short presentations, video, audience interactive discussion and gaming participation.  This symposium will focus on the latest scientific advances in our understanding of the inflammatory pathway to illustrate existing and new biologic treatments, how the safety picture of biologics as a class has evolved and how new therapeutic options interact with real-world patients and co-morbid treatment considerations for dermatologists considering these options.

The stakes are high in Montreal as we connect a little gambling with knowledge testing interactivity. Make sure you arrange a table with your friends for a little friendly competition as you wager your “derm dollars” on our audience feedback questions. Who will be the big winner at your table?

The Acne Scarring Prevention Game: Testing your Knowledge on Recent Updates in Prevention and Management Strategies

Speakers

Jerry Tan, MD, FRCPC (Chair)
Melinda Gooderham, MD, MSc, FRCPC
Roni Munk, MD, FRCPC

Learning Objectives

Recognize the prevalence and burden of scarring in patients with mild to severe acne.
Identify risk factors associated with acne scarring and outline pathophysiology of scar formation.
Outline prevention strategies for scarring in acne patients, including early interventions and evidence-based management strategies.
Describe up-to-date post-scar management strategies, including topical and modality-based options.

Program Description

This 1.5-hour accredited symposium will focus on recent updates and best practices for the prevention of atrophic scarring in acne patients, including better understanding the patient groups affected, identifying risk factors for all severity of acne, early and effective treatment options, and post-scar management strategies.  This interactive game-format symposium will include 5 rounds on specific topics.  Each round will include a game component with audience polling questions, followed by evidence-based data to support the correct answers.  The final round will test what participants learned during the symposium with top 3 participants declared the Acne Scar Prevention Champions.

  • Round 1: Prevalence, Risk Factors and Patient Impact
  • Round 2: Pathophysiology of Acne Scar Formation
  • Round 3: Current and Future Prevention Treatments
  • Round 4: Post-Scar Management Strategies
  • Round 5: Acne Scar Prevention Champions

Skin Deeper: Unravelling Important Concepts in the Discriminative and Emotional Aspects of Touch

Speakers

Co-Chair:
Melinda Gooderham, MD, MSc, FRCPC
Dermatologist, Skin Centre for Dermatology
Assistant Professor, Queen’s University
Investigator, Probity Medical Research

Co-Chair:
Irèn Kossintseva, BSc hons, MD, FRCPC, FAAD, FACMS
Mohs & Dermatologic Surgery
Clinical Instructor, Department of Dermatology & Skin Science, UBC
Director, Hair Transplant Centre, UBC

Francis McGlone, PhD
Professor of Neuroscience
Postgraduate Tutor, School of Natural Sciences and Psychology
Liverpool John Moores University, UK

Thomas E. Ungar, MD, MEd, CCFP, FCFP, FRCPC, DABPN
Clinician and Psychiatrist-in-Chief at St. Michael’s Hospital
Associate Professor of Psychiatry at the University of Toronto

Learning Objectives

Describe skin as a sensory organ that impacts both discriminative and emotional input to the brain.
Associate the neurobiology of the skin to touch as an important dimension of the dermatology patient’s overall well-being.
Reflect on the burden of skin disease to improve quality of life measures in patients beyond skin improvement.

Program Description

This multi-specialist panel discussion will bring together experts in neurobiology, dermatology, and psychiatry to scientifically review the burden of skin disease using a multi-pronged approach. Through interactive discussions and self-reflection, participants will better recognize the bias and stigma that contribute to the burden of skin diseases, and how this stigmatization can provoke feelings of depression and anxiety in those living with these diseases. A greater understanding of the impact of this burden may assist in improving a patient’s treatment outcomes.

This presentation provides an opportunity to review skin disease within a social neuroscience framework. Ongoing research on both emotional and physical components of skin disease will be discussed. Participants will review evidence demonstrating that touch is an important channel for social information, and how resistance to touch associated with skin diseases may impact quality of life and thereby affect treatment outcomes.

Following participation, dermatologists will be able to go back to their practice with a more holistic view of their patients, and how feelings of rejection, guilt, or shame due to their skin disease impact their lives and potentially their view of treatment.

Although presented patient cases may be focused on specific diseases, the discussion is designed to be applied to skin diseases in general, so that learnings may be broadly applied.

The Story of Jack and Diane

Speakers

Lorne Albrecht, MD, FRCPC (Chair)
Peter Lakatos, MD, PhD, DSc, FEBG, AGAF
Sherry Rohekar, MD, FRCPC
Sonya Abdulla, MSc, MD, FRCPC

Learning Objectives

Recognizing the systemic and chronic nature of hidradenitis suppurativa and psoriasis and the impact of comorbidities.
Acting in a timely manner to manage and decrease the risk of co-morbidities, and
Selecting the optimal therapeutic options to treat these chronic diseases and their associated co-morbidities.

Program Description

Meet Jack and Diane, people living with hidradenitis suppurativa (HS) and psoriasis respectively, for whom “the thrill of living has gone”. See their lives through the eyes of a dermatologist, rheumatologist and gastroenterologist. Through evolving case studies, the presentation will address the challenges in managing these immune-mediated inflammatory diseases beyond the visible skin issues. Participants will review the clinical evidencesand discuss how to optimally manage these chronic diseases to allow Jack and Diane, to “do the best they can”.

Agenda

8h00: Introduction: welcome, objectives and agenda
8h05: Evolving clinical case in psoriasis
8h30: Evolving clinical case in hidradenitis suppurativa
8h55: Conclusion and evaluation
End: 9h00

The Skin Microbiome: a new player in cutaneous health and disease management

Speakers

Dr. Leon Kircik
Clinical Associate Professor of Dermatology
Icahn School of Medicine at Mount Sinai, New York, NY
Indiana University Medical Center, Indianapolis, IN
Medical Director, Physicians Skin Care, PLLC Louisville, KY; DermResearch, PLLC, Louisville, KY; Skin Sciences, PLLC, Louisville, KY

Learning Objectives

The role of cutaneous microbiota harmony in maintaining a functional skin barrier.
Understand the dialogue between the skin microbiota and the immune system.
How the microbiome holds the key to understanding skincare and why to manage the skin microbiota?
Prebiotic, post biotic, and probiotic strategies

Program Description 

The exploration of the human microbiome is currently one of the fastest rising fields of medical research.

The symposium aims to describe the relationship between the skin microbiota and its potential effects on various skin diseases. The interactions between resident skin flora and the immune system are also highlighted.

Our team has pioneered different studies on the skin microbiome and the research has shown that managing the skin microbiome is an effective new way to tackle a range of skin problems including acne, psoriasis, rosacea and atopic dermatitis.

The symposium will also discuss the different strategies to manage the skin microbiota and the difference between prebiotic, postbiotic and probiotic.

Understanding this interaction presents a promising era in the field of dermatology.

Agenda
  1. Opening remarks and introduction of speakers
  2. Unveiling the role of the human microbiome
  3. Management of the skin microbiota and the relation between skin microbiome and chronic inflammatory diseases such as atopic dermatitis and acne.
  4. Novel therapeutic strategies: Prebiotic, post biotic, and probiotic strategies
  5. Key takeaways
  6. Closing remarks and questions